Recently, it has been shown that in breast cancer cells, CIP2A associates with mammalian target of rapamycin complex 1 (mTORC1) and enhances mTORC1-dependent growth signaling and inhibits autophagy independently of cMYC and AKT 37. Here, MYC is linked to breast carcinoma.